Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT01349998 · ClinicalTrials.gov registry record · Phase 3
Safety of a Topical Antifungal Treatment for Tinea Cruris, Tinea Pedis and Tinea Corporis
A Phase 3 study of Tinea Pedis and Tinea Cruris, sponsored by Tinea Pharmaceuticals.
- Completed
- Registry status
- Phase 3
- Development phase
- 604
- Enrollment target
- 20
- Study locations
NCT01349998: Completed Phase 3 study of Tinea Pedis and Tinea Cruris, sponsored by Tinea Pharmaceuticals.
NCT01349998 is a Phase 3 study of Tinea Pedis and Tinea Cruris that has completed, run by Tinea Pharmaceuticals. The registered enrollment target is 604 participants, above the 260-participant average among 9 other Tinea Pedis trials with a reported enrollment target (132% higher). The trial reports 20 study locations across 13 states. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT01349998, a Phase 3 study of Tinea Pedis and Tinea Cruris, has completed, sponsored by Tinea Pharmaceuticals.
- COMPLETED
- Registry status
- Phase 3
- Development phase
- 604 participants
- Enrollment target
- 20
- Study locations
Study Summary
The purpose of this study is to examine the long-term safety of treating recurrent episodes of tinea pedis for 14 days for each recurrence and recurrent episodes of tinea corporis or tinea cruris for 7 days for each recurrence with Product 33525.
Primary Outcome
To examine the long-term safety of treating tinea pedis, tinea corporis or tinea cruris, treatment-emergent adverse events occurring during the study will be recorded. Adverse events will be summarized by the number of subjects reporting events, system organ class, preferred term, severity, relationship to study drug, and seriousness. Baseline and end of study laboratory assessments will be conducted.
Conditions Studied
Interventions
- DRUG Product 33525
Study Locations (20)
Texas
- - Austin
- - College Station
- - Plano
- - San Antonio
Florida
- - Miami
- - Miramar
- - St. Petersburg
California
- - Fremont
- - Los Angeles
Pennsylvania
- - Hershey
- - Philadelphia
Georgia
- - Augusta
Indiana
- - Evansville
Michigan
- - Warren
Nebraska
- - Omaha
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 604 participants |
| Start Date | 2011-05 |
| Est. Completion | 2012-09 |
| Phase | Phase 3 |
What the finished NCT01349998 record still lists
NCT01349998 is an interventional study that assigns participants to a tested intervention. The registered 604 participants enrollment target is mid-sized for trials with a published cap, above the 260-participant average among 9 other Tinea Pedis trials with a reported enrollment target (132% higher).
The record links to 3 conditions, with Tinea Pedis appearing as the primary indexed condition, and to 1 intervention - of which Product 33525 is the first listed.
NCT01349998 names 20 study sites across 13 states, led by Texas, Florida, California.
Frequently Asked Questions
What is clinical trial NCT01349998 about?
NCT01349998 is a clinical study titled "Safety of a Topical Antifungal Treatment for Tinea Cruris, Tinea Pedis and Tinea Corporis". The purpose of this study is to examine the long-term safety of treating recurrent episodes of tinea pedis for 14 days for each recurrence and recurrent episodes of tinea corporis or tinea cruris for 7 days for each recurrence with Product 33525.
What is the current status of trial NCT01349998?
This trial is currently completed. It is a Phase 3 study. The enrollment target is 604 participants. The study started on 2011-05. Estimated completion is 2012-09.
What conditions does trial NCT01349998 study?
This clinical trial studies the following conditions: Tinea Pedis, Tinea Cruris, Tinea Corporis.
What interventions are being tested in trial NCT01349998?
The interventions under investigation include: Product 33525 (DRUG).
Who is sponsoring clinical trial NCT01349998?
This trial is sponsored by Tinea Pharmaceuticals, which has 2 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT01349998 being conducted?
This trial has 20 study locations across California, Florida, Georgia, Indiana, Michigan. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Tinea Pedis
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
Where NCT01349998's enrollment target sits among peer trials
604 3rd of 9 higher than 7 of 9 other Tinea Pedis trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Tinea Pedis trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
-
BE Study of Naftifine HCL
COMPLETED · Phase 3
-
Safety and Efficacy of Econazole Nitrate Foam 1% and Foam Vehicle in Subjects With Tinea Pedis
COMPLETED · Phase 3
-
A Therapeutic Equivalence Study of Ketoconazole Cream 2%
COMPLETED · Phase 3
-
Topical Tolnaftate Stick for Tinea Pedis: An Open-Label Interventional Study
RECRUITING · Phase 2
-
Safety, Tolerability, and Pharmacokinetics of UHE-103 Cream in Subjects With Tinea Cruris and/or Tinea Pedis
COMPLETED · Phase 1
-
A Study of Econazole Foam 1% in Athlete's Foot
COMPLETED · Phase 2
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT03849443 · 604 participants · Early Phase 1
Single Versus Multi-Dose Oral and Intravenous Tranexamic Acid Patients at High Risk for Blood Transfusion After Spine Surgery
- NCT05238922 · 604 participants · Phase 1
Study of INCB123667 in Subjects With Advanced Solid Tumors
- NCT06040541 · 604 participants · Phase 1
Study of RMC-9805 in Participants With KRAS G12D-Mutant Solid Tumors
- NCT02342444 · 606 participants · Phase 4
Lovenox 30 mg Twice Daily (BID) Versus 40 mg Once Daily (QD)
Similar registry start date
- NCT05988463 · started 2027-01-01 · Phase 1
Dose-Escalation Study of Artesunate Patients With IPF
- NCT07219706 · started 2026-12-10 · NA
Dietary Fiber and Time Restricted Eating
- NCT02831335 · started 2026-12-01
Technical Development of Multi-Parametric Renocerebral MRI
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia